Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 | P01008 | 3/20 | 0.54 |
| ▸ | FGF1 | P05230 | 4/20 | 0.49 |
| ▸ | FGF2 | P09038 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 8/20 | 0.43 |
| ▸ | F10 | P00742 | 5/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363878 | 0.97 | SERPINC1 (0.52) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL13039077 | 0.97 | SERPINC1 (0.52) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12920566 | 0.96 | SERPINC1 (0.51) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12920565 | 0.89 | SERPINC1 (0.43) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12606387 | 0.87 | SERPINC1 (0.43) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL13039102 | 0.83 | SERPINC1 (0.57) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL14363911 | 0.83 | SERPINC1 (0.57) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12606391 | 0.83 | SERPINC1 (0.58) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL13287036 | 0.83 | HPSE (0.42) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12606393 | 0.82 | SERPINC1 (0.60) | SERPINC1FGF1FGF2HPSEF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557968-B2 | Biotinylated hexadecasaccharides, preparation and use thereof | SANOFI (FR) | 2013-10-15 | — | — | US | disclosed |
| US-20100279960-A1 | BIOTINYLATED HEXADECASACCHARIDES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279960-A1 | BIOTINYLATED HEXADECASACCHARIDES, PREPARATION AND USE THEREOF | BTD, OSTC, FUT6 | SERPINC1 291/4885FGF1 2874/4885FGF2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.